Vivo Opportunity Fund Holdings, L.P. 13D and 13G filings for Soleno Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-31 8:00 pm Sale |
2025-03-31 | 13G | Soleno Therapeutics, Inc. SLNO |
Vivo Opportunity Fund Holdings, L.P. | 4,458,294 9.700% |
-1,833,557 (-29.14%) |
Filing |
| 2024-09-05 6:37 pm Sale |
2024-08-27 | 13G | Soleno Therapeutics, Inc. SLNO |
Vivo Opportunity Fund Holdings, L.P. | 6,291,851 16.200% |
-1,025,000 (-14.01%) |
Filing |
| 2024-05-01 1:07 pm Sale |
2024-04-29 | 13D | Soleno Therapeutics, Inc. SLNO |
Vivo Opportunity Fund Holdings, L.P. | 7,316,851 22.500% |
-1,101,242 (-13.08%) |
Filing |
| 2023-10-11 4:30 pm Unchanged |
2023-10-02 | 13D | Soleno Therapeutics, Inc. SLNO |
Vivo Opportunity Fund Holdings, L.P. | 8,418,093 30.500% |
0 (Unchanged) |
Filing |
| 2023-06-01 5:00 pm Purchase |
2023-05-25 | 13D | Soleno Therapeutics, Inc. SLNO |
Vivo Opportunity Fund Holdings, L.P. | 8,418,093 50.800% |
8,418,093 (New Position) |
Filing |